ReviewAddiction (Abingdon, England)2019
Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation.
Review in Addiction (Abingdon, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06261385 (Development of Typology-based Smoking Relapse Prevention), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of Typology-based Smoking Relapse Prevention: A Q-methodology and a Pilot Randomized Controlled Trial
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Vaping cessation interventions: a systematic review and meta-analysis.Tobacco control · 2026Pooled it
- Heated tobacco products for smoking cessation and reducing smoking prevalence.The Cochrane database of systematic reviews · 2022Pooled it
- Mobile Chat Messaging for Preventing Smoking Relapse Amid the COVID-19 Pandemic: A Pilot Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Trial
- Pilot randomized controlled trial evaluating the effect of random nicotine delivery on cigarettes per day and smoke exposure.Brain research bulletin · 2022Trial
- Medium- and longer-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial.BMC medicine · 2022Trial
- Relative effectiveness of a full versus reduced version of the 'Smoke Free' mobile application for smoking cessation: an exploratory randomised controlled trial.F1000Research · 2018Trial
- Changes in harm perceptions of e-cigarettes compared with cigarettes following the announcement of the disposable vape ban in Great Britain.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Article
- Experiences of Ex-Smokers Serving as Peer Supporters in an Instant Messaging-Based Smoking Cessation Program: A Qualitative Study.Nursing reports (Pavia, Italy) · 2026Article
- Reconsidering Ondansetron for Smoking Cessation: A Call for Renewed Investigation.Pharmacology research & perspectives · 2025Article
- Nicotine strength of e-liquids used by adult vapers in Great Britain: A population survey 2016 to 2024.Addiction (Abingdon, England) · 2025Article
- Do predictors of abstinence change in the medium- and long-term follow-up of smokers who have quit smoking? A prospective cohort study.Tobacco prevention & cessation · 2025Article
- Smoking cessation after referral from hospital to community stop smoking services: an observational study.BMJ public health · 2025Article
- Article
- Treating Tobacco Dependency in National Health Service Workers in Greater Manchester: An Evaluation of a Bespoke Digital Service.JTO clinical and research reports · 2024Article
- Classification of Lapses in Smokers Attempting to Stop: A Supervised Machine Learning Approach Using Data From a Popular Smoking Cessation Smartphone App.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Article
- Lottery incentives for smoking cessation at the workplace: design and protocol of the smoke-free lottery - a cluster randomized trial.BMC public health · 2023Article
- Right inferior frontal gyrus theta-burst stimulation reduces smoking behaviors and strengthens fronto-striatal-limbic resting-state functional connectivity: a randomized crossover trial.Frontiers in psychiatry · 2023Article
- Article
- US adult smokers' perceived relative risk on ENDS and its effects on their transitions between cigarettes and ENDS.BMC public health · 2022Article
- Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy.Psychopharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimIt is useful, for theoretical and practical reasons, to be able to specify functions for continuous abstinence over time in smoking cessation attempts. This study aimed to find the best-fitting models of mean proportion abstinent with different smoking cessation pharmacotherapies up to 52 weeks from the quit date.
methodsWe searched the Cochrane Database of Systematic Reviews to identify randomized controlled trials (RCTs) of pharmacological treatments to aid smoking cessation. For comparability, we selected trials that provided 12 weeks of treatment. Continuous abstinence rates for each treatment at each follow-up point in trials were extracted along with methodological details of the trial. Data points for each pharmacotherapy at each follow-up point were aggregated where the total across contributing studies included at least 1000 participants per data point. Continuous abstinence curves were modelled using a range of different functions from the quit date to 52-week follow-up. Models were compared for fit using R
resultsStudies meeting our selection criteria covered three pharmacotherapies [varenicline, nicotine replacement therapy (NRT) and bupropion] and placebo. Power functions provided the best fit (R
conclusionsMean continuous abstinence rates up to 52 weeks from initiation of smoking cessation attempts in clinical trials can be modelled using simple power functions for placebo, nicotine replacement therapy and bupropion and a logarithmic function for varenicline. This allows accurate prediction of abstinence rates from any time point to any other time point up to 52 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.